Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

June 4, 2026

Study Completion Date

June 4, 2026

Conditions
ChoroideremiaX-Linked Retinitis Pigmentosa
Interventions
GENETIC

BIIB111

Administered as specified in the treatment arm.

GENETIC

BIIB112

Administered as specified in the treatment arm.

Trial Locations (25)

2600

Rigshospitalet-Glostrup, Oejenafdelingen, Glostrup Municipality

10032

Columbia University Medical Center, New York

32607

Vitreo Retinal Associates PA - The Millennium Center, Gainesville

33136

University of Miami, Miami

34295

CHU Montpellier - Saint Eloi, Montpellier

53127

Universitäts-Augenklinik Bonn, Bonn

72076

Universitats Klinikum Tubingen - Institute for Ophthalmic Research, Tübingen

75012

Centre Hospitalier National d Ophtalmologie (CHNO) des Quinze-Vingts, Paris

97239

OHSU - Casey Eye Institute, Portland

90095-7065

UCLA - Jules Stein Eye Institute, Los Angeles

21287-0005

Johns Hopkins Hospital, Baltimore

02114-3002

MEEI Massachusets Eye and Ear Infirmary, Boston

45242-5664

Cincinnati Eye Institute - Blue Ash, Cincinnati

75231-5080

Retina Foundation of the Southwest, Dallas

53705-3644

University of Wisconsin School of Medicine, Madison

04039

Instituto Genetica Ocular, São Paulo

T5H 3V9

The Northern Alberta Clinical Trials and Research Centre, Edmonton

V5Z 39N

The University of British Columbia - Eye Care Centre, Vancouver

H4A 3JI

McGill University Health Centre, Montreal

00290 HUS

Helsinki University Central Hospital (HUCH), Helsinki

6525 GA

Radboudumc, Nijmegen

EC1V 2PD

Moorfields Eye Hospital, London

M13 9WL

Manchester Royal Eye Hopsital, Manchester

OX3 9DU

John Radcliffe Hospital, Oxford

SO16 6YD

Southampton General Hospital, Southampton

All Listed Sponsors
lead

NightstaRx Ltd, a Biogen Company

OTHER